FUNDAMENTAL AND CLINICAL STUDIES ON IMIPENEM/CILASTATIN SODIUM IN COMPLICATED URINARY TRACT INFECTIONS

DOI
  • KISHI MIKIO
    Department of urology, Okayama university Medical School

Bibliographic Information

Other Title
  • 複雑性尿路感染症におけるImipenem/Cilastatin sodium (MK-0787/MK-0791) の基礎的, 臨床的検討

Abstract

Fundamental and clinical studies on imipenem/cilastatin sodium (MK-0787/MK-0791), a mixture of new carbapenem antibiotic and renal dipeptidase inhibitor were performed and the following results were obtained:<BR>Minimum inhibitory concentrations of MK-0787 against 1337 strains (500 gram positive bacterias and 837 gram negative bacterias) isolated from urinary tract infections were measured and compared to those of azthreonam (AZT), cefoperazone (CPZ), ceftazidime (CAZ) and ceftizoxime (CZX). In GPCs, the antibacterial activities of MK-0787 were very strong against S. aureus, S. epidermidis, E. faecalis and other GPCs but weak against E. faecium. In GNBs, the activities against E. coli, K. pneumoniae and P. mirabilis were nearly equal to those of other drugs and far superior against E. cloacae, C. freundii and A. calcoaceticus. Similarly, this drug showed fairly stronger activities against P. aeruginosa, S. marcescens and other GNBs but showed very weak activity against X. maltophilia.<BR>MK-0787/MK-0791 were administered to 31 cases with complicated urinary tract infections for five days by drip infusion. Twenty-nine out of all cases were administered MK-0787 0.5g/MK-0791 0.5g twice a day and remaining 2 cases administered MK-0787 0.25g/MK-0791 0.25g three times a day. We evaluated 29 cases clinically by the criteria of UTI Committee and the overall clinical efficacy rate was 76%(excellent in 6 cases, moderate in 16 cases and poor in 7 cases). Bacteriologically, 25 (78%) out of 32 strains were eradcated but 7 strains appeared after the treatment.<BR>As for side effects, eruption was observed in only one case and abnormal laboratory findings were observed in 3 cases, showing transient elevation of GOT, GPT or urobilinogen.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 33 (Supplement4), 852-865, 1985

    Japanese Society of Chemotherapy

Details 詳細情報について

Report a problem

Back to top